ArticleDrug safety2020
The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance.
Article in Drug safety, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.International immunopharmacology · 2021Trial
- Artificial Intelligence and Digital Technologies Against Health Misinformation: A Scoping Review of Public Health Responses.Healthcare (Basel, Switzerland) · 2025Review
- Strategies to enhance risk communication about medicines in Malaysia: a Delphi study among multinational experts.BMC health services research · 2024Article
- Factors associated with the consumption of medicinal plants for the prevention of COVID-19 in peruvian population: a cross-sectional study.Revista peruana de medicina experimental y salud publica · 2024Article
- The effect of Covid-19 pandemic on healthcare utilization in public vs private centers in Iran: a multiple group interrupted time-series analysis.BMC health services research · 2023Article
- Global overview of pharmacist and community pharmacy actions to address COVID-19: A scoping review.Exploratory research in clinical and social pharmacy · 2023Article
- Review
- How Anti-Social Personality Traits and Anti-Establishment Views Promote Beliefs in Election Fraud, QAnon, and COVID-19 Conspiracy Theories and Misinformation.American politics research · 2023Article
- Social media and internet search data to inform drug utilization: A systematic scoping review.Frontiers in digital health · 2023Article
- ChatGPT and the rise of large language models: the new AI-driven infodemic threat in public health.Frontiers in public health · 2023Article
- Impact of risk communication on patient's safety during the pandemic.Therapeutic advances in drug safety · 2023Review
- To clarify the safety profile of paracetamol for home-care patients with COVID-19: a real-world cohort study, with nested case-control analysis, in primary care.Internal and emergency medicine · 2022Article
- Misleading Advertising of Health-Related Products in Ecuador during the COVID-19 Pandemic.Diseases (Basel, Switzerland) · 2022Article
- Assessment of A new Strategy to Prevent Prescribing Errors Involving COVID-19 Patients in Community Pharmacies.Hospital pharmacy · 2022Article
- Reflections after 2 years of COVID-19 pandemic.Reviews in medical virology · 2022Article
- Reimagining Medical Care in Assisted Living.Journal of the American Medical Directors Association · 2022Article
- Self-Reported Medication Use among Pregnant and Breastfeeding Women during the COVID-19 Pandemic: A Cross-Sectional Study in Five European Countries.International journal of environmental research and public health · 2022Article
- Perspectives on Mass Media and Governmental Measures during the 2020 COVID-19 Pandemic in a Romanian Sample of Healthcare Practitioners.Healthcare (Basel, Switzerland) · 2022Article
- Egyptian perspectives on potential risk of paracetamol/acetaminophen-induced toxicities: Lessons learnt during COVID-19 pandemic.Toxicology reports · 2022Article
- The response to the COVID-19 pandemic trusted in pharmacovigilance to diminish communication risk.Therapeutic advances in drug safety · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic that hit the world in 2020 triggered a massive dissemination of information (an "infodemic") about the disease that was channeled through the print, broadcast, web, and social media. This infodemic also included sensational and distorted information about drugs that likely first influenced opinion leaders and people particularly active on social media and then other people, thus affecting choices by individual patients everywhere. In particular, information has spread about some drugs approved for other indications (chloroquine, hydroxychloroquine, nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, favipiravir, and umifenovir) that could have led to inappropriate and therefore hazardous use. In this article, we analyze the rationale behind the claims for use of these drugs in COVID-19, the communication about their effects on the disease, the consequences of this communication on people's behavior, and the responses of some influential regulatory authorities in an attempt to minimize the actual or potential risks arising from this behavior. Finally, we discuss the role of pharmacovigilance stakeholders in emergency management and possible strategies to deal with other similar crises in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.